雲南白藥(000538.SZ):二級子公司白藥海南擬對白藥香港增資13.6億港元
格隆匯11月4日丨雲南白藥(000538.SZ)公佈,為貫徹落實《“健康中國 2030”規劃綱要》的總體部署,加快推動中國醫藥健康企業走出去步伐,公司二級全資子公司雲南白藥集團(海南)有限公司(“白藥海南”)擬對三級全資子公司雲白藥香港有限公司(“白藥香港”或“增資標的”)增資,增資金額為13.6億港元。
此次增資主要為了有效增強白藥香港的資本實力,提升其投融資能力,是雲南白藥整體改革發展戰略的延續,有利於提升雲南白藥的業務國際化水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.